

Nirav R. Shah, M.D., M.P.H. Commissioner Sue Kelly Executive Deputy Commissioner

## Attention: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective April 25, 2013, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Adderall, Accolate, Alphagan P 0.15%, Gabitril, Singulair granules, Tegretol chewable tablet,
   Trileptal suspension, and Vancocin will be added to the Program.
- Concerta will be removed from the Program and its generic will be preferred.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and **Pharmacies can submit any valid NCPDP field (408-D8) value**.

## List of Brand Name Drugs included in this program\* (Updated 4/01/13):

Accolate	Duetact	Singulair granules
Adderall & Adderall XR	Epivir	Symbyax
Alphagan P 0.15%	Felbatol	Tegretol suspension/chewable
Astelin	Gabitril	Tegretol XR
Bactroban cream	Gris-PEG	Tobradex
Carbatrol	Kadian	Tricor
Catapres - TTS	Lovenox	Trileptal suspension
Combivir	Maxalt MLT	Vancocin
Diastat	Nasacort AQ	Valtrex
Diovan HCT	Sanctura XR	Ziagen tablet

<sup>\*</sup>List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.

